For low-risk MDS, GPX4 activity of the groups treated with Fer-1 plus decitabine and Z-VAD-FMK plus decitabine was significantly higher than that of the group treated with decitabine only (Figure 6F). This evidence concerns the gene GPX4 and myelodysplastic syndrome.